Following the deaths of 18 Uzbek children, Indian pharma is once again under fire.

India, one of the largest rug exporters in the world, is looking into the company whose cough syrup has been implicated in the fatalities.
As one of the world's largest pharma exporters comes under increased criticism for the quality of the medications it produces, India has opened an investigation into the deaths of 18 youngsters in Uzbekistan who ingested an Indian-made cough syrup.
India's health ministry stated in a statement on Thursday that the Central Drugs Standard Control Organization (CDSCO), the nation's drug regulatory body, was in contact with its counterpart in Uzbekistan over the event.
The youngsters had perished after ingesting a medicinal syrup called Dok-1 Max, according to a statement released by the Uzbek health ministry on Wednesday. Dok-1 Max is a product of Indian pharmaceutical company Marion Biotech Pvt Ltd. It said that preliminary analyses revealed the syrup contained ethylene glycol, a hazardous chemical that has previously been connected to child fatalities.
The Uttar Pradesh Drug Control and CDSCO teams jointly inspected Marion Biotech's Noida facility as soon as they received the information, the Indian government said in a statement on Thursday. "Further action as appropriate would be initiated based on the inspection report," it added. Noida lies in the northern state of Uttar Pradesh and is a suburb of the capital city of New Delhi. The Indian ministry said samples of the cough syrup had been taken for testing.
A spokesperson of the World Health Organization (WHO) said that the organisation is “in contact with health authorities in Uzbekistan and is ready to assist in further investigations”.
The Indian media cited Hasan Harris, a legal counsel of Mario Biotech, as saying that the production of the medicine had been stopped.
The incident occurred months after a cough syrup manufactured by Maiden Pharmaceuticals Ltd. in New Delhi was blamed for the deaths of 70 children in the Gambia, but both the firm and the Indian government disputed any issues with the drug's quality. Maiden was blacklisted by Vietnam in 2014.
India is a major supplier of drugs to several developing and middle-income countries. Africa receives 45% of all generic medications from India. Over the past ten years, its pharmaceutical exports have more than doubled.
